RedHill Biopharma Ltd.
RDHL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $7 | $62 | $86 |
| % Growth | 23.2% | -89.4% | -27.9% | – |
| Cost of Goods Sold | $3 | $3 | $33 | $49 |
| Gross Profit | $5 | $3 | $28 | $36 |
| % Margin | 60.3% | 47% | 46.1% | 42.4% |
| R&D Expenses | $2 | $4 | $7 | $29 |
| G&A Expenses | $15 | $29 | $55 | $77 |
| SG&A Expenses | $16 | $31 | $64 | $88 |
| Sales & Mktg Exp. | $1 | $2 | $9 | $11 |
| Other Operating Expenses | $2 | -$44 | $0 | $0 |
| Operating Expenses | $19 | -$10 | $71 | $117 |
| Operating Income | -$15 | $13 | -$43 | -$81 |
| % Margin | -181.7% | 193.4% | -69.3% | -94.6% |
| Other Income/Exp. Net | $6 | $11 | -$29 | -$17 |
| Pre-Tax Income | -$8 | $24 | -$72 | -$98 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | $24 | -$72 | -$98 |
| % Margin | -102.8% | 366.2% | -116% | -114% |
| EPS | -7 | 46 | -600 | -1,000 |
| % Growth | -115.2% | 107.7% | 40% | – |
| EPS Diluted | -7 | 46 | -600 | -1,000 |
| Weighted Avg Shares Out | 2 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $41 | $17 |
| Depreciation & Amortization | $1 | $2 | $8 | $18 |
| EBITDA | -$8 | $26 | -$22 | -$63 |
| % Margin | -94.4% | 402.3% | -35.9% | -73.5% |